ClinConnect ClinConnect Logo
Search / Trial NCT06570070

AI-powered Chatbot vs. Human Counselors in Smoking Cessation

Launched by BEIJING NORMAL UNIVERSITY · Aug 22, 2024

Trial Information

Current as of June 26, 2025

Not yet recruiting

Keywords

ClinConnect Summary

This clinical trial is looking to compare the help provided by an AI-powered chatbot to that of human counselors for people trying to quit smoking. The goal is to see if the chatbot can be effective and helpful for smokers in the community. If you're a smoker aged 18 or older, live in Zhuhai for at least the next six months, and use a smartphone with a WeChat account, you might be eligible to participate. However, if you have trouble communicating or are currently enrolled in other smoking cessation programs, you won't be able to join.

Participants in this study can expect to receive support for quitting smoking either from the chatbot or a human counselor. It's a great opportunity to explore new ways to get help in your journey to stop smoking. The trial is not yet recruiting, so if you’re interested, keep an eye out for updates!

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. aged 18 and above, reside in Zhuhai for the next 6 months;
  • 2. smoke at least 1 cigarette or use e-cigarettes daily;
  • 3. Having a smartphone and a WeChat account, being able to use WeChat skillfully.
  • Exclusion Criteria:
  • 1. Smokers who have communication barrier (either physically or cognitively);
  • 2. Smokers who are currently participating in other SC programmes or services

About Beijing Normal University

Beijing Normal University is a prestigious academic institution in China, renowned for its commitment to advancing research and education across various disciplines, including the fields of health and life sciences. As a clinical trial sponsor, the university leverages its extensive expertise, state-of-the-art facilities, and collaborative networks to facilitate innovative research initiatives. By fostering partnerships with healthcare institutions and industry stakeholders, Beijing Normal University aims to contribute to the development of cutting-edge therapeutic solutions, enhance patient outcomes, and promote public health through rigorous clinical investigations.

Locations

Zhuhai, Guangdong, China

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported